In the pharmaceutical industry, regulatory compliance refers to adherence to a structured set of requirements and principles governing the management of medicinal products and the scientific information associated with them.
Within this framework, Medical Information plays a particularly important role, as it is responsible for providing scientific content that must be accurate, verifiable, and consistent with approved product information. Therefore, compliance is not merely a formal requirement. Instead, it is essential for ensuring reliability, transparency, and the appropriate use of medicines.
Regulatory requirements and compliance framework
Medical Information activities operate within a broad regulatory environment that includes European pharmacovigilance guidelines, industry codes of practice, and national regulatory requirements.
At the European level, the Good Pharmacovigilance Practices (GVP) establish fundamental principles for the management of safety information, including requirements related to data quality, documentation, and traceability. In parallel, regulations such as Directive 2001/83/EC and its subsequent amendments provide the overall framework for the management of medicinal products and related scientific information.
In addition to regulatory requirements, industry codes of conduct, including those issued by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and national organizations, define key principles for scientific communication. In particular, they emphasize a non-promotional approach that is supported by scientific evidence.
Within this context, Medical Information activities must ensure that information provided about medicinal products is:
- Based on up-to-date scientific evidence;
- Presented in a balanced and non-promotional manner;
- Consistent with approved information, such as the Summary of Product Characteristics (SmPC);
- Managed through documented and traceable processes.
As a result, compliance in Medical Information is not an additional requirement but an integral part of the process. It must be maintained throughout every stage of inquiry management, from information collection to the preparation of the final response.
Compliance risks in Medical Information
Managing scientific inquiries involves several areas that may create compliance risks if not properly controlled.
One of the most significant risks is the use of outdated information. This may involve the Summary of Product Characteristics, global company documents, or scientific literature. Consequently, responses may no longer reflect the most current evidence available.
Another key risk relates to the lack of balance in scientific communications. Responses that emphasize the benefits of a medicinal product without adequately addressing associated risks or adverse reactions may be considered non-compliant and, in some situations, may be viewed as inappropriate from a regulatory perspective.
Particular attention must also be given to off-label inquiries, meaning requests related to uses that fall outside approved indications. In these situations, a rigorous approach is required. Appropriate scientific wording and the use of relevant disclaimers are essential to avoid any promotional interpretation.
In addition, traceability remains a critical element. Inadequate documentation of requests and responses, or the absence of a structured recording system, can compromise the ability to demonstrate compliance and may represent a significant risk during audits or regulatory inspections.
How Medical Information ensures compliance
To mitigate these risks, Medical Information relies on structured processes and established quality controls.
Responses are typically developed from approved standard responses, which undergo scientific and regulatory review and are periodically updated based on the latest evidence. Furthermore, inquiries are managed through dedicated systems that ensure documentation and traceability throughout the entire process.
Standard Operating Procedures (SOPs) provide detailed guidance on inquiry handling, including source selection criteria, management of off-label requests, and requirements for response review and approval.
At the same time, Medical Information works closely with other departments, including Pharmacovigilance, Regulatory Affairs, and Medical Affairs, to ensure consistency between scientific content, safety data, and medical strategy.
Consequently, compliance is not a retrospective control activity. Rather, it is embedded within the process itself through established standards, procedures, and quality systems.
Conclusions
Medical Information is positioned at the center of a highly regulated process in which the management of scientific information requires rigor, oversight, and accountability.
Ensuring compliance means integrating regulatory requirements, content quality, and traceability into every operational step while avoiding informal or unstructured approaches.
From this perspective, Medical Information is far more than a support function. It serves as a key safeguard for maintaining consistency, reliability, and compliance in scientific communications, contributing directly to patient safety and the credibility of the pharmaceutical industry.
References
- European Medicines Agency (EMA) – Good Pharmacovigilance Practices (GVP), Module VI: Management and Reporting of Adverse Reactions
- European Commission – Directive 2001/83/EC (as amended) on Medicinal Products for Human Use
- European Federation of Pharmaceutical Industries and Associations (EFPIA) – Code of Practice
- Italian Medicines Agency (AIFA) – Pharmacovigilance and National Regulatory Framework
- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) – Code of Practice
- European Medicines Agency (EMA) – Guidance on Scientific Information Exchange and Interactions with Healthcare Professionals